Sugi Predict

Sugi Predict / Compounds / SCHEMBL5142483

SCHEMBL5142483

SCHEMBL5142483

CC1CN(Cc2nc(Nc3ccc(S(=O)(=O)N4CCOCC4)cc3)c3ncc(-c4ncccc4Cl)cc3n2)CC(C)O1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ TRPV1 Q8NER1 10/20 0.51
▸ TRPV4 Q9HBA0 1/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ PKM P14618 1/20 0.38
▸ CXCR5 P32302 1/20 0.38
▸ APLNR P35414 1/20 0.38
▸ HTT P42858 1/20 0.38
▸ CCR6 P51684 1/20 0.38
▸ NPSR1 Q6W5P4 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ BUB1 O43683 1/20 0.38
▸ SHMT2 P34897 1/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ AURKA O14965 1/20 0.37
▸ AURKB Q96GD4 1/20 0.37
▸ CCNE1 P24864 1/20 0.37
▸ CDK2 P24941 1/20 0.37
▸ GAA P10253 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14283377 1.00 TRPV1 (0.51) TRPV1TRPV4KDM4EPKMCXCR5
SCHEMBL14336157 0.91 TRPV1 (0.60) TRPV1TRPV4
SCHEMBL14283343 0.88 TRPV1 (0.57) TRPV1
SCHEMBL4976007 0.88 TRPV1 (0.57) TRPV1
SCHEMBL4971893 0.86 TRPV1 (0.44) TRPV1TRPV4KDM4EPKMCXCR5
SCHEMBL4976360 0.84 TRPV1 (0.61) TRPV1KDM4EHTT
SCHEMBL14283276 0.84 TRPV1 (0.61) TRPV1KDM4EHTT
SCHEMBL4976439 0.84 TRPV1 (0.59) TRPV1
SCHEMBL14283273 0.84 TRPV1 (0.59) TRPV1
SCHEMBL5146117 0.84 TRPV1 (0.71) TRPV1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7074799-B2 Substituted quinazolin-4-ylamine analogues NEUROGEN CORPORATION (US) 2006-07-11 — — US claimed
EP-1471910-A2 SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES AS MODULATORS OF CAPSAICIN RECEPTORS NEUROGEN CORPORATION (US) 2004-11-03 — — EP claimed
US-20040106616-A1 Substituted quinazolin-4-ylamine analogues NEUROGEN CORPORATION 2004-06-03 — — US claimed
WO-2003062209-A2 SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES AS MODULATORS OF CAPSAICIN NEUROGEN CORPORATION (US) 2003-07-31 — — WO claimed
US-7304059-B2 Substituted quinazolin-4-ylamine analogues NEUROGEN CORPORATION (US) 2007-12-04 — — US disclosed
US-20060173003-A1 Substituted quinazolin-4-ylamine analogues NEUROGEN CORPORATION (US) 2006-08-03 — — US disclosed
US-7074799-B2 Substituted quinazolin-4-ylamine analogues NEUROGEN CORPORATION (US) 2006-07-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060173003-A1 Substituted quinazolin-4-ylamine analogues PIGS, HRH4, GPR88 TRPV1 244/4885TRPV4 500/4885KDM4E 2662/4885
US-20040106616-A1 Substituted quinazolin-4-ylamine analogues PIGS, HRH4, GPR88 TRPV1 240/4885TRPV4 516/4885KDM4E 3001/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.